Pomdoctor Reports Significant Revenue Growth in FY 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 14 2026
0mins
Source: PRnewswire
- Revenue Growth: Pomdoctor's net revenues for FY 2025 reached RMB 399.9 million (approximately $57.2 million), marking a 16.7% year-over-year increase, primarily driven by robust growth in its Internet hospital business, particularly online pharmacy sales, indicating the company's market potential in chronic disease management.
- Increased R&D Investment: The company increased its R&D investments by 328.5% year-over-year to RMB 12.9 million (approximately $1.8 million), aimed at enhancing technology-driven healthcare capabilities and platform infrastructure, thereby supporting long-term strategic goals and improving service efficiency.
- Rising Operating Expenses: Total operating expenses for FY 2025 amounted to RMB 170.9 million (approximately $24.4 million), significantly up from RMB 73.5 million in FY 2024, reflecting strategic investments in IPO-related costs and marketing efforts, despite resulting in a net loss.
- Optimistic Market Outlook: Pomdoctor remains optimistic about the long-term growth potential of China's digital healthcare market, planning to deepen strategic partnerships with pharmaceutical companies to drive Internet hospital growth and integrate online medical insurance systems for sustainable development and long-term value creation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy POM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on POM
About POM
PomDoctor Ltd is a company that mainly operates an online medical services platform for chronic diseases. The Company's business model focuses on chronic disease management and pharmaceutical services, forming a one-stop medical service platform that connects patients with doctors and pharmaceutical products. It helps patients to conveniently connect with doctors and obtain one-stop medical services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pomdoctor Adjusts ADS Ratio to 1-for-3
- ADS Ratio Change: Pomdoctor Limited has announced an adjustment to its American Depositary Shares (ADS) ratio effective June 22, 2026, changing from one ADS representing one-sixth of a Class A ordinary share to one ADS representing three Class A ordinary shares, implementing a 1-for-18 reverse ADS split aimed at enhancing shareholder value.
- Trading Structure Update: Following the adjustment, the new ADS will continue to trade under the ticker “POM” on Nasdaq and will receive a new CUSIP identifier of 73181R207, ensuring that investors can easily identify and trade the newly structured shares.
- Price Expectations: Management anticipates that the new share structure will drive an increase in the trading price of the ADS, although they cannot guarantee that the post-split value will remain at or above eighteen times the pre-split price, reflecting a mix of optimism and uncertainty in the market regarding future valuations.
- Shareholder Impact: While the fundamentals of the Class A ordinary shares remain unchanged, this ADS ratio adjustment may affect the existing shareholders' equity structure, prompting them to reassess their investment strategies to adapt to the new market environment.
See More
POMDOCTOR Announces ADS Ratio Change
- ADS Ratio Change: POMDOCTOR announced that its American Depositary Shares (ADS) will change from one ADS representing one-sixth of a Class A ordinary share to one ADS representing three Class A ordinary shares effective June 22, 2026, which equates to an 18-for-1 reverse split aimed at enhancing the ADS trading price.
- Automatic Exchange Mechanism: On the effective date, existing ADS holders will have their ADSs automatically exchanged for new ADSs without any action required on their part, a process managed by the depositary bank Citibank, N.A., ensuring a smooth transition.
- Market Trading Impact: While the ADS trading price is expected to increase proportionally, the company cannot assure that the post-change price will equal or exceed eighteen times the pre-change price, which may affect investor return expectations.
- Industry Position: POMDOCTOR ranks sixth in China's Internet hospital market in 2022, focusing on chronic disease management and pharmaceutical services, aiming to enhance the efficiency and transparency of healthcare services through its one-stop platform, thereby solidifying its market position.
See More
POMDOCTOR Announces ADS Ratio Change
- ADS Ratio Change: POMDOCTOR announced that its American Depositary Shares (ADS) ratio will change on June 22, 2026, from one ADS representing one-sixth of a Class A ordinary share to one ADS representing three Class A ordinary shares, which is expected to positively impact the ADS trading price.
- Automatic Exchange Mechanism: On the effective date, existing ADS will be automatically exchanged for new ADS, requiring no action from ADS holders, with the process managed by the depositary bank Citibank, N.A., ensuring a smooth transition.
- Market Reaction Expectations: While the company anticipates a proportional increase in the ADS trading price, it does not guarantee that the new price will equal or exceed eighteen times the pre-adjustment price, reflecting a cautious market sentiment regarding this change.
- Industry Position: POMDOCTOR ranks sixth in China's Internet hospital market, focusing on chronic disease management and pharmaceutical services, aiming to enhance the efficiency and transparency of healthcare services through its one-stop platform, thereby solidifying its market position.
See More
Pomdoctor Changes ADS Ratio to 1:3
- ADS Ratio Change: Pomdoctor plans to change its American Depositary Shares (ADS) ratio from 1 ADS representing 1/6 of a Class A share to 1 ADS representing 3 Class A shares, effectively functioning as a 1-for-18 reverse split for existing ADS holders, expected to take effect on June 22, 2026.
- Market Reaction: Following this announcement, Pomdoctor's shares fell 4.6% in premarket trading, indicating investor concerns regarding this significant adjustment, which may impact the company's performance in the capital markets.
- Impact on Investors: This change in ADS ratio could dilute existing shareholders' stakes, potentially affecting their confidence in the company's future growth, especially in the current market environment where investors are increasingly sensitive to capital structure changes.
- Strategic Implications: By adjusting the ADS ratio, Pomdoctor may aim to enhance its stock liquidity and market appeal; although the stock price has declined in the short term, this move could facilitate better financing conditions in the capital markets in the long run.
See More
Pomdoctor Limited Reports 16.7% Revenue Growth in FY 2025
- Revenue Growth: Pomdoctor Limited reported net revenues of RMB 399.9 million (approximately USD 57.2 million) for FY 2025, marking a 16.7% increase from RMB 342.6 million in FY 2024, indicating robust growth potential in the market.
- Gross Profit Increase: The gross profit for FY 2025 was RMB 52.3 million (approximately USD 7.5 million), up 9.6% from RMB 47.7 million in FY 2024, reflecting effective strategies in cost control and product pricing.
- Gross Margin Decline: The gross margin for FY 2025 was 13.1%, down from 13.9% in FY 2024, suggesting that the company faces pressure on profitability and needs to focus on future cost management.
- Loss Per Share Improvement: The basic and diluted loss per share for FY 2025 was RMB 21.96 (approximately USD 3.14), an improvement from RMB 22.72 in FY 2024, demonstrating the company's efforts and effectiveness in reducing losses.
See More
Pomdoctor Reports Significant Revenue Growth in FY 2025
- Revenue Growth: Pomdoctor's net revenues for FY 2025 reached RMB 399.9 million (approximately $57.2 million), marking a 16.7% year-over-year increase, primarily driven by robust growth in its Internet hospital business, particularly online pharmacy sales, indicating the company's market potential in chronic disease management.
- Increased R&D Investment: The company increased its R&D investments by 328.5% year-over-year to RMB 12.9 million (approximately $1.8 million), aimed at enhancing technology-driven healthcare capabilities and platform infrastructure, thereby supporting long-term strategic goals and improving service efficiency.
- Rising Operating Expenses: Total operating expenses for FY 2025 amounted to RMB 170.9 million (approximately $24.4 million), significantly up from RMB 73.5 million in FY 2024, reflecting strategic investments in IPO-related costs and marketing efforts, despite resulting in a net loss.
- Optimistic Market Outlook: Pomdoctor remains optimistic about the long-term growth potential of China's digital healthcare market, planning to deepen strategic partnerships with pharmaceutical companies to drive Internet hospital growth and integrate online medical insurance systems for sustainable development and long-term value creation.
See More
Pomdoctor Adjusts ADS Ratio to 1-for-3
- ADS Ratio Change: Pomdoctor Limited has announced an adjustment to its American Depositary Shares (ADS) ratio effective June 22, 2026, changing from one ADS representing one-sixth of a Class A ordinary share to one ADS representing three Class A ordinary shares, implementing a 1-for-18 reverse ADS split aimed at enhancing shareholder value.
- Trading Structure Update: Following the adjustment, the new ADS will continue to trade under the ticker “POM” on Nasdaq and will receive a new CUSIP identifier of 73181R207, ensuring that investors can easily identify and trade the newly structured shares.
- Price Expectations: Management anticipates that the new share structure will drive an increase in the trading price of the ADS, although they cannot guarantee that the post-split value will remain at or above eighteen times the pre-split price, reflecting a mix of optimism and uncertainty in the market regarding future valuations.
- Shareholder Impact: While the fundamentals of the Class A ordinary shares remain unchanged, this ADS ratio adjustment may affect the existing shareholders' equity structure, prompting them to reassess their investment strategies to adapt to the new market environment.
See More
POMDOCTOR Announces ADS Ratio Change
- ADS Ratio Change: POMDOCTOR announced that its American Depositary Shares (ADS) will change from one ADS representing one-sixth of a Class A ordinary share to one ADS representing three Class A ordinary shares effective June 22, 2026, which equates to an 18-for-1 reverse split aimed at enhancing the ADS trading price.
- Automatic Exchange Mechanism: On the effective date, existing ADS holders will have their ADSs automatically exchanged for new ADSs without any action required on their part, a process managed by the depositary bank Citibank, N.A., ensuring a smooth transition.
- Market Trading Impact: While the ADS trading price is expected to increase proportionally, the company cannot assure that the post-change price will equal or exceed eighteen times the pre-change price, which may affect investor return expectations.
- Industry Position: POMDOCTOR ranks sixth in China's Internet hospital market in 2022, focusing on chronic disease management and pharmaceutical services, aiming to enhance the efficiency and transparency of healthcare services through its one-stop platform, thereby solidifying its market position.
See More
POMDOCTOR Announces ADS Ratio Change
- ADS Ratio Change: POMDOCTOR announced that its American Depositary Shares (ADS) ratio will change on June 22, 2026, from one ADS representing one-sixth of a Class A ordinary share to one ADS representing three Class A ordinary shares, which is expected to positively impact the ADS trading price.
- Automatic Exchange Mechanism: On the effective date, existing ADS will be automatically exchanged for new ADS, requiring no action from ADS holders, with the process managed by the depositary bank Citibank, N.A., ensuring a smooth transition.
- Market Reaction Expectations: While the company anticipates a proportional increase in the ADS trading price, it does not guarantee that the new price will equal or exceed eighteen times the pre-adjustment price, reflecting a cautious market sentiment regarding this change.
- Industry Position: POMDOCTOR ranks sixth in China's Internet hospital market, focusing on chronic disease management and pharmaceutical services, aiming to enhance the efficiency and transparency of healthcare services through its one-stop platform, thereby solidifying its market position.
See More
Pomdoctor Changes ADS Ratio to 1:3
- ADS Ratio Change: Pomdoctor plans to change its American Depositary Shares (ADS) ratio from 1 ADS representing 1/6 of a Class A share to 1 ADS representing 3 Class A shares, effectively functioning as a 1-for-18 reverse split for existing ADS holders, expected to take effect on June 22, 2026.
- Market Reaction: Following this announcement, Pomdoctor's shares fell 4.6% in premarket trading, indicating investor concerns regarding this significant adjustment, which may impact the company's performance in the capital markets.
- Impact on Investors: This change in ADS ratio could dilute existing shareholders' stakes, potentially affecting their confidence in the company's future growth, especially in the current market environment where investors are increasingly sensitive to capital structure changes.
- Strategic Implications: By adjusting the ADS ratio, Pomdoctor may aim to enhance its stock liquidity and market appeal; although the stock price has declined in the short term, this move could facilitate better financing conditions in the capital markets in the long run.
See More
Pomdoctor Limited Reports 16.7% Revenue Growth in FY 2025
- Revenue Growth: Pomdoctor Limited reported net revenues of RMB 399.9 million (approximately USD 57.2 million) for FY 2025, marking a 16.7% increase from RMB 342.6 million in FY 2024, indicating robust growth potential in the market.
- Gross Profit Increase: The gross profit for FY 2025 was RMB 52.3 million (approximately USD 7.5 million), up 9.6% from RMB 47.7 million in FY 2024, reflecting effective strategies in cost control and product pricing.
- Gross Margin Decline: The gross margin for FY 2025 was 13.1%, down from 13.9% in FY 2024, suggesting that the company faces pressure on profitability and needs to focus on future cost management.
- Loss Per Share Improvement: The basic and diluted loss per share for FY 2025 was RMB 21.96 (approximately USD 3.14), an improvement from RMB 22.72 in FY 2024, demonstrating the company's efforts and effectiveness in reducing losses.
See More
Pomdoctor Reports Significant Revenue Growth in FY 2025
- Revenue Growth: Pomdoctor's net revenues for FY 2025 reached RMB 399.9 million (approximately $57.2 million), marking a 16.7% year-over-year increase, primarily driven by robust growth in its Internet hospital business, particularly online pharmacy sales, indicating the company's market potential in chronic disease management.
- Increased R&D Investment: The company increased its R&D investments by 328.5% year-over-year to RMB 12.9 million (approximately $1.8 million), aimed at enhancing technology-driven healthcare capabilities and platform infrastructure, thereby supporting long-term strategic goals and improving service efficiency.
- Rising Operating Expenses: Total operating expenses for FY 2025 amounted to RMB 170.9 million (approximately $24.4 million), significantly up from RMB 73.5 million in FY 2024, reflecting strategic investments in IPO-related costs and marketing efforts, despite resulting in a net loss.
- Optimistic Market Outlook: Pomdoctor remains optimistic about the long-term growth potential of China's digital healthcare market, planning to deepen strategic partnerships with pharmaceutical companies to drive Internet hospital growth and integrate online medical insurance systems for sustainable development and long-term value creation.
See More
